Suboptimal dosing of strattera (Atomoxetine) for ADHD patients

Postgraduate Medicine

Volumn 126, Issue 5, 2014, Pages 197-199

  Clemow, David B ^a  

^a Lilly USA   (United States)

Author keywords

ADHD; Atomoxetine; Dose; Dosing

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL EFFECTIVENESS; DRUG DOSE TITRATION; DRUG TOLERABILITY; FUNCTIONAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; RATING SCALE; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOSE RESPONSE; HUMAN; TIME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PROPYLAMINES; TIME FACTORS;

EID: 84921871231     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.09.2814     Document Type: Article

References (12)

1. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83, 1-9.
2. Wietecha LA, Williams DW, Herbert M, Melmed RD, Greenbaum M, Schuh K. Atomoxetine treatment in adolescents with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(6):719-730.
3. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120.
4. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
5. Data on file, Lilly Research Laboratories, STR20081007a.
6. IMS Health, Processing and Data Delivery System-National Disease and Therapeutic Index; Strattera weighted average daily dose over time report, January 2006-December 2013.
7. Alatorre C, Kabul S, Montejano L, Kelsey D. Real world dosing patterns of atomoxetine in adults with attention-deficit/hyperactivity disorder. Abstract. World Congress of Psychiatry, September 14-18, 2014. Madrid, Spain.
8. Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med. 2005;352(2):165-173.
9. Market Strategies International; Strattera marketplace tracker W2. 2014 report.
10. Wietecha LA, Ruff DD, Allen AJ, Greenhill LL, Newcorn JH. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies: a meta-analysis of company-sponsored studies. J Clin Psychiatry. 2013;74(12):1217-1223.
11. Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila). 2009;48(7):723-733.
12. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2009;29(1):44-50.